June 24, 2025
Cidara Announces Proposed Public Offering of Common Stock
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary…
Pharmaceuticals, Biotechnology and Life Sciences
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary…
CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer and…
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing…
Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase…
Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kitsHead-to-head comparison of iMDx’s digital PCR-based test kits with…
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for…
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin…
CHICAGO, June 21, 2025 (GLOBE NEWSWIRE) — Abvance Therapeutics, a biotechnology company developing next generation glucagon analogs and therapies to…
Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined companyCRANFORD, N.J. and LOMBARD, Ill., June…